What We Like About Cubist Pharma

We are carefully entering portfolio positions in this environment. (Note: Portfolio positions vs. trading positions) A company that we like for its specialty product is Cubist Pharmaceuticals (CBST). It has made all of our screens recently, but we were reluctant to add it to portfolios as the very recent trends have been down, down, down. The official line from the company’s description page:

Cubist Pharmaceuticals, Inc. (Cubist), is a biopharmaceutical company focused on the research, development and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. The Company’s products are used primarily in hospitals but also may be used in acute care settings including home-infusion and hospital outpatient clinics. Cubist has one marketed product, an intravenous (IV) antibiotic, CUBICIN (daptomycin for injection). CUBICIN is approved in the United States for the treatment of complicated skin and skin structure infections (cSSSI), caused by Staphylococcus aureus (S. aureus) and certain other Gram-positive bacteria, and for blood-stream infections (bacteremia), including right-sided infective endocarditis, caused by methicillin susceptible and methicillin resistant S. aureus (MSSA and MRSA).